Traders should await the actual earnings release and management commentary on March 19 for any material updates on cash runway, trial progress, or funding plans. Absence of data makes this pre-announcement low impact.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $6.15entry
- T+1 · 8mo ago −3.90%α −3.30% · $5.91
- T+5 · 8mo ago +1.63%α +2.60% · $6.25
- T+20 · 7mo ago +18.54%α +16.56% · $7.29
- T+60 · 5mo ago −3.25%α −13.95% · $5.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 financial results. The press release contains no actual financial data, guidance, or material business updates, serving only as a notification of the upcoming earnings event.
Key Facts
- Relmada Therapeutics will host a conference call on March 19, 2026, at 4:30 PM ET to discuss Q4 and full-year 2025 financial results.
- No financial results, guidance, or material operational updates were disclosed in the press release.
- The company remains in clinical-stage development with lead candidates NDV-01 and sepranolone in mid-stage trials.
Financial Impact
None disclosed, no financial figures released
Risk Factors
- Lack of disclosed financials increases information asymmetry ahead of the call.
- Clinical-stage biotech with no near-term revenue, stock remains highly speculative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254447 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Viewing Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers